GlassScriptPhysician profile
Manasi Kadam Ladrigan
NPI 1366457814
$12,654.84
in general payments reported to CMS, 2019-2025
33 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $522 · 2021: $829 · 2022: $6,792 · 2023: $1,084 · 2024: $1,319 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $4,165.00 | 2022 | |
| Genzyme Corporation | $1,917.96 | 2022-2025 | |
| Abbvie INC. | $1,688.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $986.73 | 2019-2025 | |
| Amgen INC. | $609.36 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $510.29 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $410.43 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $358.93 | 2020-2025 | Tremfya |
| Pfizer INC. | $205.86 | 2019-2025 | |
| Celgene Corporation | $178.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $169.47 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $168.78 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $164.31 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $135.27 | 2019-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.17 | 2022-2024 | Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.93 | 2022-2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $81.14 | 2019 | |
| Dermavant Sciences, INC. | $71.60 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $69.18 | 2019-2022 | |
| Almirall LLC | $50.99 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $46.73 | 2022 | |
| Arcutis Biotherapeutics, INC. | $44.78 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $42.53 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $40.90 | 2023-2024 | Ycanth |
| Smith+Nephew, INC. | $35.87 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $24.48 | 2023 | Hemangeol |
| Botanix Sb INC | $21.77 | 2025 | Sofdra |
| Blueprint Medicines Corporation | $21.35 | 2022 | |
| Biofrontera INC. | $17.21 | 2021 | |
| Vyne Pharmaceuticals INC. | $15.55 | 2021 | |
| Dusa Pharmaceuticals, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manasi Ladrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.